Disposable plastic labware is ubiquitous in contemporary pharmaceutical research laboratories. Plastic labware is routinely used for chemical compound storage and during automated liquid-handling processes that support assay development, high-throughput screening, structure-activity determinations, and liability profiling. However, there is little information available in the literature on the contaminants released from plastic labware upon DMSO exposure and their resultant effects on specific biological assays. The authors report here the extraction, by simple DMSO washing, of a biologically active substance from one particular size of disposable plastic tips used in automated compound handling. The active contaminant was identified as erucamide ((Z)-docos-13-enamide), a long-chain mono-unsaturated fatty acid amide commonly used in plastics manufacturing, by gas chromatography/mass spectroscopy analysis of the DMSO-extracted material. Tip extracts prepared in DMSO, as well as a commercially obtained sample of erucamide, were active in a functional bioassay of a known G-protein-coupled fatty acid receptor. A sample of a different disposable tip product from the same vendor did not release detectable erucamide following solvent extraction, and DMSO extracts prepared from this product were inactive in the receptor functional assay. These results demonstrate that solvent-extractable contaminants from some plastic labware used in the contemporary pharmaceutical research and development (R&D) environment can be introduced into physical and biological assays during routine compound management liquid-handling processes. These contaminants may further possess biological activity and are therefore a potential source of assay-specific confounding artifacts. (Journal of Biomolecular Screening 2009:566-572) 
INTRODUCTION
P lastic materials are widely used in the manufacturing and packaging of pharmaceutical products. Although plastics are generally preferred due to their chemical inertness, trace amounts of releasing agents and lubricants are known to be present in these plastic products, and interactions between plastic materials and pharmaceutical products are well documented. 1 Much caution is taken because of the effects that extractables (substances that can be released under aggressive conditions) and leachables (substances spontaneously released under normal conditions) may have on the safety and/or toxicity of consumer products, including pharmaceuticals. 2, 3 Indeed, considerable public attention recently has been focused on this problem following reports of the leaching of bisphenols from polycarbonate beverage containers. 4, 5 Although disposable plastic products are important during the manufacturing and packaging of drug products, they are also extensively used in the pharmaceutical research and development (R&D) stage. Drug discovery compounds are routinely stored in plastic vessels and transferred to assay plates using disposable polypropylene plastic pipette tips. In our typical compound management (CM) process, compounds from therapeutic area medicinal chemists are solubilized in glass vials using DMSO and transferred to polypropylene plates via automated liquid handlers. The samples in polypropylene plates are then replicated into low-volume assay-ready plates containing 0.2 to 1.0 µL compound, again using automated pipetting systems equipped with disposable plastic tips, for biological assays that include primary and secondary screening, lead compound optimization, and liability testing.
Liquid-handling processes are tested extensively and validated before deployment to the R&D organization to ensure consistency and accuracy of the dispensing. In addition, processes are checked for compatibility with the downstream assays that they support. Therefore, it was unexpected when sample plates prepared using a validated process began producing anomalous results in a nephelometry assay, our standard assay for compound aqueous solubility. Careful testing of each component of the assay process identified one particular size of disposable pipette tip, used in the CM compound plating process for the assay, as the source of the problem. Using a combination of nuclear magnetic resonance (NMR) and gas chromatography/mass spectroscopy (GC/MS) analytical techniques, we were able to specifically extract erucamide, a fatty acid amide routinely used as a slip agent in the manufacture of certain plastic products, 6,7 from these pipette tips by DMSO. We further report that the extracts prepared from the problematic tips were also active in a cell-based functional bioassay for a G-protein-coupled receptor, as was a commercially obtained sample of erucamide. Erucamide could not be identified in extracts prepared from samples of a different pipette tip obtained from the same vendor, and these extracts were inactive in the receptor bioassay. These results demonstrate that potentially interfering substances can be introduced into drug discovery assays by leaching from specific components of a compoundhandling process under routine conditions. These substances may also possess biological activity, which may in turn cause bioassay-specific confounding artifacts.
MATERIALS AND METHODS

Nephelometry
Dry compounds in glass vials were solubilized in 100% DMSO to a concentration of 20 mM and diluted to 3 mM in Falcon 96-well polypropylene plates (#353263, BD Biosciences, Franklin Lakes, NJ). Compounds were subsequently reformatted into 384-well polypropylene master plates (#23490-104, REMP, Durham, NC) and were serially diluted in 100% DMSO with a Tecan Genesis (Durham, NC) fitted with standard nonremovable tips to create 10-point concentration-response curves (2-fold serially diluted, 3 mM top concentration) located in columns 1 to 10 and 11 to 20, respectively. Background wells were located in columns 21 to 24. Duplicate assay-ready daughter plates (#353285, BD Biosciences) were created from the master plates on the day of the assay by transferring 500 nL of the 100% DMSO samples from the master plates to daughter plates on a BioCel system with a VPrep (384 disposable tip head) fitted with 50-µL disposable plastic tips (#06881-002, Velocity11, Palo Alto, CA). Between the replication of each daughter plate, the pipette tips were washed with water followed by a wash with 100% DMSO. The daughter plates were then diluted 1:100 by the addition of 50 µL of 37 °C phosphate-buffered saline (PBS) to bring the final DMSO concentration to 1%. The diluted samples were then thoroughly mixed and analyzed for particulate formation using a Gentest FACSOL Solubility Scanner (BD Biosciences). The Solubility Scanner measures 90° light scatter from a 635-nm 3-mW diode laser to detect particle formation and captures each scatter event independently to produce individual scatter profiles for each sample. The limit of solubility is defined as the lowest concentration where relative particulate counts are >3 times the relative particulate counts of blank wells.
Extraction and proton NMR analysis
To identify the contaminant responsible for the nephelometry assay interference, we soaked approximately fifty of the 50-µL VPrep polypropylene tips (Velocity11) in 1:1 chloroform-methanol and sonicated them at room temperature for 30 min. The chloroform-methanol mixture was chosen as a strong solvent to extract as much material as possible from the tips for identification of the compound class. Following solvent evaporation, proton NMR analysis was conducted with a Bruker DRX 500-MHz spectrometer (CDCl 3 ) using a 5-mm glass NMR tube with a 0.5-mL sample volume (Wilmad LabGlass, Buena, NJ). Untreated glass labware was used exclusively during sample extraction and analysis to avoid potential crosscontamination of the plastic samples under investigation.
Extraction and GC/MS analysis
To elucidate the chemical structure of the contaminant and to provide additional evidence that the contaminant could be released by our normal compound-handling process, we extracted samples of the 50-µL VPrep polypropylene tips (#06881-002, Velocity11) with DMSO. Tips were cut into small pieces (0.3 g total) and inserted into triplicate 1-dram glass vials containing 1 mL of 99.9% DMSO. The tips were sonicated for 1.5 h and then soaked overnight at room temperature. The solvent was evaporated under a nitrogen stream for 72 h, and the residue was redissolved in a chloroform-methanol 1:1 mixture for transfer to a GC sample vial and analyzed by in-line GC/MS. The GC/MS system comprised a LEAP Technologies GC PAL autosampler (Carrboro, NC), an Agilent Technologies 6890N GC (Wilmington, DE), and a Waters Micromass GCT Premier time-of-flight mass spectrometer (Milford, MA). The GC column was an Agilent DB5-MS (0.18 mm × 20 m, 0.18 µm), and the carrier gas was helium. The GC inlet was set at 250 °C and a split ratio of 50. The GC column was initially set at 85 °C for 1 min and then ramped at 7 °C/min to 320 °C. After a 3-min solvent delay, positive electron impact ionization with 70eV ion energy and a scan range from m/z 50-800 was employed. The GC/MS operating software was MassLynx 4.1, and the NIST Mass Spectral Library Version 2.0/2005 was used for compound identification. As a control, samples of a different size of disposable VPrep polypropylene tip (70 µL, #06881-002, Velocity11) were extracted and analyzed as described above. Untreated glass labware was used exclusively during sample extraction and analysis to avoid potential cross-contamination.
Cell culture and cAMP accumulation bioassay
HEK293 cells expressing human G-protein-coupled receptor cDNAs were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum and antibiotics at 37 °C in an atmosphere of 5% CO 2 . All cell culture reagents were from Invitrogen (Carlsbad, CA). The day of the assay, cells were detached from the culture flask with trypsin, washed, and resuspended in an assay buffer composed of Hank's buffered saline solution (HBSS) and 25 mM HEPES. Isobutyl-3-methyxanthine (IBMX, Sigma-Aldrich, St. Louis, MO) was added to 1 mM to inhibit cellular phosphodiesterase activity. For cAMP determinations, dried pipette tip extracts (0.1-0.3 mg) were dissolved in DMSO to a concentration of 3 mg/mL. Test compounds (10 mM) and dried extracts were serially diluted in DMSO and dispensed into 384-well assay plates, followed by a 40-µL addition of cell suspension containing 5000 cells. After a 30-min room temperature incubation, cAMP accumulation was terminated by the addition of 20 µL of 1.5% Triton X-100 in HBSS. Then, 4 µL of the lysed cellular extract was transferred to a low-volume 384-well assay plate, and cAMP was measured using a homogeneous timeresolved fluorescence (HTRF) assay kit (CIS-US, Inc., Bedford, MA) and an EnVision plate reader equipped with a 337-nm excitation laser (PerkinElmer, Waltham, MA). Raw HTRF ratio values were converted to cAMP concentrations using a standard curve (cAMP concentration range 500,000-0.85 pM). Concentrationresponse curves were fit using a 4-point logistic (GraphPad Prism 4.03, GraphPad, La Jolla, CA).
RESULTS AND DISCUSSION
The initial indication of a problem in our compound-handling process was the observation of elevated plate backgrounds in a nephelometry assay, a light-scattering assay used to determine aqueous compatibility and solubility. 8 This was unexpected because the assay had received extensive validation prior to deployment and had been performed weekly for approximately 3 years without issue. Heat maps from the nephelometry assay (Fig. 1A,B ) illustrate the high plate background and interference extending across the plate that was seen in the first daughter plates replicated from a set of master plates (Fig. 1A) but not in subsequent daughter plates following the washing of tips that occurs between each daughter plate replicated, as described in Materials and Methods (Fig. 1B) . The interference can also be seen in the high background particulate levels observed in the compound graphs from the first daughter plates replicated from a set of master plates, as illustrated by the red and blue analysis indicator bars at 30,000 and 14,000 relative particulate units (RPU) that are set at 3 times the average background calculated from the average of columns 21 to 24 (Fig. 1C) . Following the washing of tips, the background of subsequent daughter plates returns to the more typical level of <1000 RPU seen in Figure 1D . The elevated background particulate counts in the initial daughter plates made accurate determinations of compound solubility impossible due to the erratic nature of the solubility curves (Fig. 1C) , whereas subsequent daughter plates behaved as expected for the assay (Fig. 1D) .
To identify the source of the problem, we examined our entire compound-handling process, including the disposable automated liquid handler pipette tips used to prepare the assay plates for the nephelometry solubility assay. Because the nephelometry assay provided the first indication of a potential problem in our compound-handling process, the same assay was used to identify the source of the interference. It was noticed that the first set of daughter plates replicated for the assay was reproducibly associated with the interference regardless of its position within the performance of the nephelometry assay run. Using a process of elimination, we determined that the 50-µL VPrep polypropylene pipette tips were the only piece of labware that was consistently associated with the anomalous effects in the nephelometry assay. Other components of our compound replication process, including the plastic compound storage and dilution plates, were not associated with anomalous nephelometry assay effects. Also, when the nephelometry assay compound replication process was modified to use 30-µL VPrep disposable tips, the interference associated with the 50-µL tips was not observed (data not shown).
To identify the active contaminant, we extracted samples of the 50-µL VPrep tips in a mixture of chloroform/methanol (1:1) to release sufficient material for proton NMR analysis. Initial proton NMR analysis suggested that the sample was a mono-unsaturated fatty acid derivative: 1 To determine the chemical structure of the contaminant identified by NMR, we subjected samples of 2 different VPrep pipette tips, 50-µL tips associated with the mono-unsaturated fatty acid and 70-µL tips, to extraction in DMSO to approximate normal compound-handling processes. The resulting extracts were dried, resuspended in chloroform-methanol, and analyzed by GC/MS. These results are shown in Figure 2 . Dioctylphthalate, a common laboratory contaminant, was identified as the compound at 24.2 min retention time in all 3 samples. The unknown species at 26.9 min in the chromatogram in Figure 2C (50-µL tip extract) and the associated MS spectrum in Figure 2D were identified as (Z)-docos-13-enamide (erucamide) via a NIST Mass Spectral Library search. A reference sample of erucamide confirmed the assignment using retention time and spectral matching (data not shown). The accurate mass measurement of the observed radical cation is consistent with the proposed structure, C 22 H 43 NO, M +⋅ at m/z 337.3351, calculated 337.3345, ∆ppm 1.8. This substance was not present in the DMSO blank or the 70-µL tip sample. Erucamide is a fatty acid amide used in plastics manufacture as an nonblocking slip agent. 6, 7 We have since learned, as a result of extensive conversations with the vendor, that the 50-µL and 70-µL VPrep polypropylene tips are produced by different manufacturers. Significantly, we were also able to learn that the vendor had changed manufacturers of the 50-µL VPrep tips shortly before we began to experience problems in our compound solubility assay.
Erucamide is similar in chain length and in placement of the cis-double-bond to another endogenous mono-unsaturated fatty acid amide, oleoylethanolamide (OEA, N-(2-hydroxyethyl)-9Z-octadecenamide). OEA, as well as related fatty acid Nacylethanolamides such as anadamide, has biological activity at multiple cellular proteins, including receptors and ion channels. [9] [10] [11] Similarly, erucamide has previously been reported to possess angiogenic and fluid homeostatic activity in vivo. 12, 13 Accordingly, we next sought to determine whether we could demonstrate biological activity of erucamide and OEA at a common biological target. Commercially obtained samples of erucamide and OEA as well as the erucamide-containing DMSO extracts prepared from the 50-µL pipette tips were tested for the ability to stimulate cyclic AMP (cAMP) accumulation in cells expressing a G-protein-coupled receptor (GPCR) known to be activated by fatty acid ligands. The extracts prepared from the 50-µL VPrep tips, but not the 70-µL tips, were capable of stimulating cAMP accumulation in the receptor-expressing cells (Fig. 3A,B) . A commercially obtained sample of erucamide was shown to stimulate cAMP accumulation in the same cells with an efficacy similar to OEA, although the potency of erucamide (EC 50 9.3 µM) was about 10-fold weaker than that of OEA (EC 50 0.83 µM, Fig. 3D ). Finally, we tested erucamide in a cAMP accumulation assay with an unrelated (non-fatty acid) GPCR. Erucamide was completely inactive in this assay (data not shown), demonstrating that the effects of erucamide in the cAMP accumulation assay are receptor specific. These results demonstrate that the amount of erucamide released from the 50-µL VPrep tips under relatively gentle conditions (extraction in DMSO) is sufficient to be detected in a routine bioassay of receptor function. In addition, our results raise the intriguing possibility that erucamide and OEA may exert some of their observed biological effects through a common molecular target(s).
Even though we identified erucamide following extraction (vortexing) of samples of the 50-µL compound-handling pipette tips with DMSO, it seems likely that significant amounts of erucamide are leached from these tips during normal compound-handling processes. Erucamide is poorly soluble, even in DMSO, and assay-ready plates, containing 500 nL of test compound, prepared with the 50-µL VPrep tips but not a 30-µL VPrep tip, consistently displayed increased light scattering in the nephelometry assay. However, it remains formally possible that a second, unidentified contaminant also found only on the 50-µL disposable tips is responsible for the interference in the nephelometry assay.
Recently, another primary fatty acid amide, oleamide ((Z)octa-9-decenamide), which is also used as a slip agent in plastics manufacture, was identified as a leachate from disposable plastic tubes that was capable of inhibiting monoamine oxidase B. 14 This observation, taken together with our results, indicates that certain chemical additives commonly used in the manufacture of particular items of plastic labware can cause assayspecific interferences; moreover, these substances can manifest as either activators (agonists) or inhibitors (antagonists). It is not necessarily the case that these recent identifications of assay contamination by plastic labware leachates are due to changes in plastic manufacturing because detection of sometimes subtle assay interference has been greatly facilitated by improvements in biological and biophysical assay detection sensitivity. Because we examined only a small number of examples of the total plastic labware used in our CM facility, the scope of this particular problem (assay contamination by leached erucamide) is difficult to gauge. Nevertheless, the widespread use of various chemical slip and releasing agent additives in laboratory plastics manufacture, coupled with the apparent assay-specific actions of some of these contaminants, emphasizes the importance of ongoing scientific vigilance when attempting to resolve confounding assay results, including a thorough examination of the entire process chain from compound plating and replication through assay performance. As a consequence of this experience, our CM "best practices" have been expanded to include more extensive testing and increased communication with downstream assay stakeholders when any process components, such as plastic tips and plates, are replaced even with ostensibly equivalent products. Indeed, scrutiny is increased even when there is a change in the lot number of a plastic product used in one of our CM processes.
Modern drug discovery research is a system of partnerships between pharmaceutical companies and the vendors of assay consumables and technology on whose products we depend. Increased sensitivity on the part of assay-consumable suppliers and producers to the problem of unwanted product contamination that can be introduced during plastics manufacturing is also necessary to avoid erroneous results and resultant increases in cycle time during new compound identification and characterization. The recent introduction of highly polished molds in the manufacturing of pharmaceutical research consumables by some producers is an interesting step in this direction. However, we would also recommend that the technical specifications of laboratory consumables include full disclosure of the additives, especially slip and release agents, used in their manufacture.
